Ocriplasmin Brand Name– JETREA
What is Ocriplasmin
Ocriplasmin is a proteolytic enzyme approved for the treatment of symptomatic vitreomacular adhesion (VMA).
Ocriplasmin is administered via ophthalmic intravitreal injection only. This is the first drug to receive FDA-approval for the treatment of VMA.
Ocriplasmin (Jetrea) was approved by the FDA in October 2012.
Indications
- vitreomacular adhesion
For the treatment of symptomatic vitreomacular adhesion
Side Effects
- blurred vision
- cataracts
- conjunctival hyperemia
- dyschromatopsia
- iritis
- lens subluxation
- macular edema
- night blindness
- ocular hemorrhage
- ocular hypertension
- ocular infection
- ocular inflammation
- ocular irritation
- ocular pain
- photophobia
- photopsia
- retinal detachment
- retinal edema
- visual impairment
- xerophthalmia
Monitoring Parameters
- intraocular pressure
Contraindications
- breast-feeding
- children
- glaucoma
- infants
- neonates
- ocular infection
- ocular surgery
- pregnancy
Interactions
There are no drug interactions associated with Ocriplasmin products.
